Free Trial
NASDAQ:CVAC

CureVac (CVAC) Stock Price, News & Analysis

CureVac logo
$5.38 -0.01 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$5.42 +0.04 (+0.65%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CureVac Stock (NASDAQ:CVAC)

Advanced

Key Stats

Today's Range
$5.38
$5.41
50-Day Range
$5.34
$5.48
52-Week Range
$2.37
$5.72
Volume
351,007 shs
Average Volume
430,007 shs
Market Capitalization
$1.21 billion
P/E Ratio
5.60
Dividend Yield
N/A
Price Target
$6.83
Consensus Rating
Hold

Company Overview

CureVac Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

CVAC MarketRank™: 

CureVac scored higher than 71% of companies evaluated by MarketBeat, and ranked 298th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CureVac has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.

  • Upside Potential

    CureVac has a consensus price target of $6.83, representing about 27.0% upside from its current price of $5.38.

  • Amount of Analyst Coverage

    CureVac has only been the subject of 1 research reports in the past 90 days.

  • Read more about CureVac's stock forecast and price target.
  • Earnings Growth

    Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CureVac is 5.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 82.64.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CureVac is 5.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.66.

  • Price to Book Value per Share Ratio

    CureVac has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CureVac's valuation and earnings.
  • Percentage of Shares Shorted

    1.27% of the float of CureVac has been sold short.
  • Short Interest Ratio / Days to Cover

    CureVac has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CureVac has recently increased by 2.54%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CureVac does not currently pay a dividend.

  • Dividend Growth

    CureVac does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.27% of the float of CureVac has been sold short.
  • Short Interest Ratio / Days to Cover

    CureVac has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CureVac has recently increased by 2.54%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 1 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CureVac insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.15% of the stock of CureVac is held by insiders.

  • Percentage Held by Institutions

    Only 17.26% of the stock of CureVac is held by institutions.

  • Read more about CureVac's insider trading history.
Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVAC Stock News Headlines

CureVac: The Hidden Value Of The mRNA Wallet
Buy alert: Move $1,000 before Tesla’s Optimus launch
Elon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.tc pixel
CureVac sees cash runway into 2028
See More Headlines

CVAC Stock Analysis - Frequently Asked Questions

CureVac's stock was trading at $3.41 on January 1st, 2025. Since then, CVAC shares have increased by 57.8% and is now trading at $5.38.

CureVac N.V. (NASDAQ:CVAC) announced its quarterly earnings data on Thursday, August, 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.15. The business earned $1.41 million during the quarter, compared to analysts' expectations of $4.27 million. CureVac had a net margin of 38.21% and a trailing twelve-month return on equity of 29.57%.

CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

CureVac's top institutional shareholders include Green Alpha Advisors LLC (0.01%).

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

Last Earnings
8/21/2025
Today
10/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CVAC
CIK
1809122
Employees
880
Year Founded
2000

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+26.7%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.96
Trailing P/E Ratio
5.62
Forward P/E Ratio
7.49
P/E Growth
N/A
Net Income
$175.50 million
Net Margins
38.21%
Pretax Margin
42.22%
Return on Equity
29.57%
Return on Assets
25.41%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
6.17
Quick Ratio
6.16

Sales & Book Value

Annual Sales
$579.18 million
Price / Sales
2.09
Cash Flow
$0.88 per share
Price / Cash Flow
6.15
Book Value
$3.36 per share
Price / Book
1.61

Miscellaneous

Outstanding Shares
224,340,000
Free Float
219,515,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
2.51

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CVAC) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners